Gilead Sciences (NASDAQ:GILD) Releases Earnings Results, Beats Estimates By $0.51 EPS

Gilead Sciences (NASDAQ:GILD) issued its earnings results on Tuesday. The biopharmaceutical company reported ($6.75) EPS for the quarter, topping the consensus estimate of ($7.26) by $0.51, Zacks reports. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.During the same period in the previous year, the company earned $2.01 earnings per share. The business’s revenue for the quarter was up 10.6% compared to the same quarter last year. Gilead Sciences updated its FY 2026 guidance to -0.650–0.300 EPS.

Here are the key takeaways from Gilead Sciences’ conference call:

• Base business sales rose 10% year over year to $7.6 billion, prompting Gilead to raise its 2026 base-business sales outlook to $29.8 billion–$30.1 billion and total product sales outlook to $30.1 billion–$30.4 billion.
• HIV sales grew 12%, with quarterly PrEP revenue exceeding $1 billion for the first time and Yeztugo achieving more than 70% six-month reinjection persistence. Gilead raised its full-year HIV growth forecast to 9%–10% and continues to expect approximately $1 billion in 2026 Yeztugo sales.
• Trodelvy sales increased 26% to $457 million, supported by demand in breast cancer and new first-line metastatic triple-negative breast cancer approvals. Livdelzi sales more than doubled to $167 million, while positive IDEAL results could expand its PBC opportunity.
• The company highlighted several potential growth catalysts, including an expected August FDA decision for once-daily BIC/LEN, a potential 2027 launch for once-weekly oral HIV treatment, and a December 23 FDA decision for anito-cel in multiple myeloma.
• Cell therapy sales fell 14% year over year to $417 million amid competitive pressure, particularly for Tecartus. Acquisitions of Arcellx, Tubulis, and Ouro generated approximately $11.2 billion in acquired IPR&D expenses, driving reported non-GAAP EPS to negative $6.75 and full-year EPS guidance to negative $0.65–negative $0.30.

Gilead Sciences Trading Up 3.1%

Shares of GILD traded up $4.10 on Tuesday, reaching $135.25. 10,084,002 shares of the company’s stock were exchanged, compared to its average volume of 7,149,559. The business has a 50 day moving average price of $129.58 and a two-hundred day moving average price of $136.11. Gilead Sciences has a 12 month low of $108.46 and a 12 month high of $157.29. The stock has a market capitalization of $167.92 billion, a P/E ratio of 18.43 and a beta of 0.32. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead reported a quarterly loss of $6.75 per share, which was better than analysts’ expected loss of approximately $7.07–$7.26 per share. Product sales increased 8% year over year and exceeded Wall Street estimates, providing support for the shares. Gilead Sciences Reports Q2 Loss, Beats Revenue Estimates
• Positive Sentiment: HIV medicines delivered double-digit sales growth. Yeztugo, Gilead’s newer HIV pre-exposure prophylaxis drug, narrowly beat sales expectations, keeping attention on its potential to become a major long-term growth driver. Gilead’s High-Profile HIV Drug Beat
• Positive Sentiment: California’s highest court ruled in Gilead’s favor in a product-liability case, finding that drugmakers do not have a legal duty to develop an even safer alternative when an existing medicine is considered safe. The decision reduces a potentially significant legal risk. California Court Rules for Gilead
• Neutral Sentiment: Gilead posted a quarterly loss because of costs associated with recent acquisitions, although its underlying operating performance benefited from stronger HIV demand. Gilead Second-Quarter Sales Rise
• Negative Sentiment: Management lowered its full-year Veklury forecast after sales of the COVID-19 treatment plunged 81% in the quarter. This highlights continuing pressure on a legacy revenue stream. Gilead Swings to Loss on R&D Costs
• Negative Sentiment: Full-year revenue guidance of $30.1 billion to $30.4 billion is below the $30.5 billion analyst consensus, which may limit enthusiasm despite better-than-expected EPS guidance. AIDS Healthcare Foundation also criticized Gilead’s pricing and business practices, adding reputational pressure. AHF Crowns Gilead Corporate Welfare King

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on GILD. Barclays lowered their price target on shares of Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating for the company in a report on Wednesday, July 29th. Weiss Ratings lowered Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, May 28th. Truist Financial lowered their target price on Gilead Sciences from $157.00 to $156.00 and set a “buy” rating for the company in a research note on Tuesday, July 7th. Cantor Fitzgerald restated an “overweight” rating on shares of Gilead Sciences in a research report on Wednesday, July 29th. Finally, Rothschild & Co Redburn cut their price target on Gilead Sciences from $170.00 to $167.00 in a research note on Monday, May 11th. Twenty-five equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $157.93.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction on Friday, May 15th. The shares were sold at an average price of $131.29, for a total transaction of $3,676,120.00. Following the completion of the sale, the insider owned 125,779 shares of the company’s stock, valued at approximately $16,513,524.91. The trade was a 18.21% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the company’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $130.31, for a total transaction of $1,954,650.00. Following the sale, the chief executive officer owned 592,133 shares of the company’s stock, valued at $77,160,851.23. The trade was a 2.47% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 82,000 shares of company stock valued at $10,641,790. 0.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Gilead Sciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Bank of America Corp DE boosted its holdings in shares of Gilead Sciences by 15.2% in the fourth quarter. Bank of America Corp DE now owns 23,121,620 shares of the biopharmaceutical company’s stock valued at $2,837,948,000 after buying an additional 3,046,688 shares during the period. Amundi raised its holdings in shares of Gilead Sciences by 25.5% during the fourth quarter. Amundi now owns 9,520,135 shares of the biopharmaceutical company’s stock worth $1,168,501,000 after acquiring an additional 1,936,354 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in shares of Gilead Sciences by 4.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 27,698,660 shares of the biopharmaceutical company’s stock worth $3,399,734,000 after acquiring an additional 1,195,269 shares during the period. Bank of Nova Scotia lifted its position in Gilead Sciences by 371.4% in the 4th quarter. Bank of Nova Scotia now owns 1,227,279 shares of the biopharmaceutical company’s stock valued at $150,636,000 after acquiring an additional 966,905 shares in the last quarter. Finally, Raymond James Financial Inc. boosted its stake in Gilead Sciences by 50.6% in the 4th quarter. Raymond James Financial Inc. now owns 2,734,917 shares of the biopharmaceutical company’s stock worth $336,007,000 after purchasing an additional 919,106 shares during the period. Institutional investors own 83.67% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.